[Federal Register Volume 59, Number 10 (Friday, January 14, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-908]


[[Page Unknown]]

[Federal Register: January 14, 1994]


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES
 

Prospective Grant of Exclusive License: Cell Stress 
Transcriptional Factors

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive world-wide license to practice the invention embodied in 
U.S. Patent Application SN 07/617,910, entitled ``Cell Stress 
Transcriptional Factors'' to StressTech Biomedical, Inc. of San 
Francisco, CA. The patent rights in this invention have been assigned 
to the United States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
It is anticipated that this license will be limited to the fields of 
commercial screening assay services and kits provided to third parties. 
This prospective exclusive license may be granted unless within 60 days 
from the date of this published notice, NIH receives written evidence 
and argument that establishes that the grant of the license would not 
be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.
    The patent application is based upon the observation that 
activation of heat shock proteins in an organism indicates elevated or 
environmental temperatures or a variety of other environmental 
stresses. Activation involves binding of a heat shock factor (HSF) to 
heat shock elements (HSE) and consequent transcription of heat shock 
genes. This method for detecting the accumulation of HSF in the nucleus 
of stressed cells involves novel activators for Drosophilia and human 
HSF, polynucleotides encoding those activators, and antibodies to 
natural and recombinant DNA. The method may also be used to monitor and 
diagnose the effects of abnormal stresses, including disease, on cells.

ADDRESSES: Requests for a copy of this patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Mr. Steven M. Ferguson, Technology Licensing 
Specialist, Office of Technology Transfer, National Institutes of 
Health, Box OTT, Bethesda, MD 20892. Telephone: (301) 496-7735; 
Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be 
required to receive a copy of the patent application. Applications for 
a license in the indicated exclusive fields filed in response to this 
notice will be treated as objections to the grant of the contemplated 
license. Only written comments and/or applications for a license which 
are received by NIH within sixty (60) days of this notice will be 
considered.

    Dated: January 3, 1994.
Donald P. Christoferson,
Acting Director, Office of Technology Transfer.
[FR Doc. 94-908 Filed 1-13-94; 8:45 am]
BILLING CODE 4140-01-M